Research map: The therapeutic approach to cardiovascular–kidney–metabolic syndrome

Back to the article

Papers in this map

  1. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization · Alan S. Go · 2004 · 11471 citations · Cited by this paper
  2. Community power building to reduce inequities in access to health care · 2026 · Related
  3. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance · Jaakko O. Tuomilehto · 2001 · 10983 citations · Cited by this paper
  4. Insights from integrative spatial transcriptomics in sepsis-associated acute kidney injury · 2026 · Related
  5. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure · Bertram Pitt · 1999 · 9199 citations · Cited by this paper
  6. Sequential therapeutic approach for the management of osteoporosis in people with chronic kidney disease · 2026 · Related
  7. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · Paul E. Stevens · 2024 · 8239 citations · Cited by this paper
  8. A path to reduce chronic kidney disease burden in Samoa · 2026 · Related
  9. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure · John J.V. McMurray · 2014 · 6987 citations · Cited by this paper
  10. The first-in-human combined bladder and kidney transplant · 2026 · Related
  11. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction · Bertram Pitt · 2003 · 4965 citations · Cited by this paper
  12. Clinical practice recommendations for the diagnosis and management of nephropathic cystinosis · 2026 · Related
  13. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms · Faiez M. Zannad · 2010 · 3115 citations · Cited by this paper
  14. The versatile roles of long non-coding RNAs in kidney disease · 2026 · Related
  15. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes · George L. Bakris · 2020 · 2886 citations · Cited by this paper
  16. Large language models in healthcare · 2026 · Related
  17. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure · Theresa A. McDonagh · 2023 · 2438 citations · Cited by this paper
  18. Incretin-based therapies for the treatment of obesity-related diseases · 2024 · Related
  19. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk · Robert H. Eckel · 2013 · 2268 citations · Cited by this paper
  20. Epidemiology of cardiovascular–kidney–metabolic syndrome · 2026 · Related
  21. Arterial and Cardiac Aging: Major Shareholders in Cardiovascular Disease Enterprises · Edward G. Lakatta · 2003 · 2246 citations · Cited by this paper
  22. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association · Chiadi E. Ndumele · 2023 · 2076 citations · Cited by this paper
  23. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure · Deepak L. Bhatt · 2020 · 1873 citations · Cited by this paper
  24. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial · Adrian F. Hernandez · 2018 · 1848 citations · Cited by this paper
  25. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · Vlado Perkovic · 2024 · 1826 citations · Cited by this paper
  26. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes · Bertram Pitt · 2021 · 1742 citations · Cited by this paper
  27. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials · Søren Lund Kristensen · 2019 · 1676 citations · Cited by this paper
  28. Bariatric Surgery and Long-term Cardiovascular Events · Lars Sjöström · 2012 · 1652 citations · Cited by this paper
  29. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity · Mikhail Kosiborod · 2023 · 1621 citations · Cited by this paper
  30. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association · Chiadi E. Ndumele · 2023 · 1330 citations · Cited by this paper
  31. Kidney Disease and Increased Mortality Risk in Type 2 Diabetes · Maryam Afkarian · 2013 · 1310 citations · Cited by this paper
  32. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis · Rajiv Agarwal · 2021 · 1298 citations · Cited by this paper
  33. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease · Deepak L. Bhatt · 2020 · 1207 citations · Cited by this paper
  34. Development and Validation of the American Heart Association’s PREVENT Equations · Sadiya S. Khan · 2023 · 1163 citations · Cited by this paper
  35. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial · Marc Alan Pfeffer · 2014 · 1068 citations · Cited by this paper
  36. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis · Ele Ferrannini · 2016 · 993 citations · Cited by this paper
  37. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials · Muthiah Vaduganathan · 2022 · 982 citations · Cited by this paper
  38. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy · Zhikai Zheng · 2024 · 982 citations · Cited by this paper
  39. Strict Blood-Pressure Control and Progression of Renal Failure in Children · The ESCAPE Trial Group · 2009 · 961 citations · Cited by this paper

Source: OpenAlex (CC0)